MRNA logo Moderna +
Moderna
+

Moderna (MRNA) Business News

Track Moderna in real time with a live news feed covering Moderna stock news, official press releases, company announcements, and an archive of historical Moderna news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
7:00 AM | Tuesday | Sep 1, 2026 Accesswire

Moderna to Present at Upcoming Conferences in September 2026

News Thumbnail
7:00 AM | Friday | Aug 28, 2026 Accesswire

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

News Thumbnail
7:20 AM | Thursday | Aug 27, 2026 Accesswire

Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes

News Thumbnail
6:45 AM | Wednesday | Aug 19, 2026 Business Wire

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

News Thumbnail
11:00 AM | Tuesday | Aug 4, 2026 Accesswire

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

News Thumbnail
7:00 AM | Friday | Jul 31, 2026 Accesswire

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates

News Thumbnail
7:00 AM | Thursday | Jul 16, 2026 Accesswire

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

News Thumbnail
7:00 AM | Thursday | Jul 9, 2026 Accesswire

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

News Thumbnail
7:00 AM | Wednesday | Jul 8, 2026 Accesswire

Moderna Appoints Michael McDonnell to Board of Directors

News Thumbnail
7:00 AM | Friday | Jun 26, 2026 Newsfile Corp

From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak

News Thumbnail

Moderna to Present at Upcoming Conferences in September 2026

Accesswire

7:00 AM | Tuesday | Sep 1, 2026

news photo
Loading...

CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m.

Read full article redirect
7:00 AM | Tuesday | Sep 1, 2026

Moderna to Present at Upcoming Conferences in September 2026

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a.m. ET Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.m.

Read full article arrow
News Thumbnail
7:00 AM | Friday | Aug 28, 2026

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Accesswire

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna has also purchased a hedge overlay intended to offset dilution up to a cap initially equal to a 175.0% premium to the stock price at pricing CAMBRIDGE, MA / ACCESS Newswire / August 28, 2026 / Moderna, Inc. (NASDAQ:MRNA) ("Moderna"), today announced the pricing of $2.6 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
The offering was upsized from the previously announced offering size of $2.0 billion... Read more

Read full article arrow
News Thumbnail
7:20 AM | Thursday | Aug 27, 2026

Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes

Accesswire

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt Moderna will also purchase a hedge overlay intended to offset dilution up to a cap initially equal to at least a 150% premium to the stock price at pricing CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) ("Moderna"), today announced that it intends to offer, subject to market conditions and other factors, $2.0 billion aggregate principal amount of Convertible Senior Notes due 2032 (the "notes") in a private placement (the "offering") only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Moderna also intends... Read more

Read full article arrow
News Thumbnail
6:45 AM | Wednesday | Aug 19, 2026

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

Business Wire

RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's a.

Read full article arrow
News Thumbnail
11:00 AM | Tuesday | Aug 4, 2026

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus

Accesswire

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines indicated Phase 1 trial is being conducted in Canada as part of our expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), building on Moderna's prior filovirus research CAMBRIDGE, MA / ACCESS Newswire / August 4, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that following Health Canada's authorization of the study, the first participants have been vaccinated in a Phase 1 clinical study in Canada evaluating mRNA-1469, the Company's investigational mRNA vaccine being evaluated to prevent Bundibugyo ebolavirus, or BDBV, disease. The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic.

Read full article arrow
News Thumbnail
7:00 AM | Friday | Jul 31, 2026

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates

Accesswire

Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) Reiterates plan to deliver up to 10% revenue growth in 2026 Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.
7 - 5.2 billion Anticipates potential approval of Moderna's fifth product with the August 5th PDUFA date for mFLUSIVA, the Company's seasonal influenza vaccine candidate Announces that mRNA-1403, Moderna's norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis and the Company is preparing to enroll an additional cohort CAMBRIDGE, MA / ACCESS Newswire / July 31, 2026 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second... Read more

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jul 16, 2026

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.

Read full article arrow
News Thumbnail
7:00 AM | Thursday | Jul 9, 2026

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

Accesswire

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.

Read full article arrow
News Thumbnail
7:00 AM | Wednesday | Jul 8, 2026

Moderna Appoints Michael McDonnell to Board of Directors

Accesswire

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.

Read full article arrow
News Thumbnail
7:00 AM | Friday | Jun 26, 2026

From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak

Newsfile Corp

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors

Read full article arrow
News Thumbnail